| 1 |
NCT02169830 |
Recruiting |
Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine |
|
- Drug: nortriptyline
- Drug: Topiramate
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- evaluate the comparative effectiveness of migraine diet, nortriptyline and topiramate
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02169830 |
24482_ Vest_Migraine |
|
June 2014 |
June 30, 2020 |
December 2020 |
June 23, 2014 |
September 6, 2018 |
|
- Saint Louis University
Saint Louis, Missouri, United States
|
|
| 2 |
NCT03015753 |
Recruiting |
The Efficacy of Tai Chi Training for the Prophylaxis of Migraine in Chinese Women |
|
- Behavioral: Tai Chi training
- Other: Waiting list control group
|
Interventional
|
Not Applicable |
- The Hong Kong Polytechnic University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The difference in frequency of migraine attacks (the number of attacks per month)
- The proportion of responders
- Duration of headache attack
- (and 17 more...)
|
60 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT03015753 |
G-UA8P |
|
February 2016 |
April 2017 |
July 2017 |
January 10, 2017 |
January 11, 2017 |
|
- The Hong Kong Polytechnic University
Hung Hom, Hong Kong
|
|
| 3 |
NCT03484871 |
Recruiting |
Resting-state Functional Connectivity Changes During Migraine Treatment |
|
|
Observational
|
|
- Samsung Medical Center
- SK Chemicals Co.,Ltd.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- functional MRI imaging changes
- structural MRI imaging changes
- Functional and structural correlates of treatment response
- (and 2 more...)
|
30 |
Female |
18 Years to 50 Years (Adult) |
NCT03484871 |
2016-04-028 |
|
May 2016 |
November 2018 |
November 2018 |
April 2, 2018 |
April 2, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 4 |
NCT03716505 |
Not yet recruiting |
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines |
|
- Device: gammaCore Sapphire active
- Device: gammaCore Sapphire Sham
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Safety and effectiveness of gammaCore Sapphire as a treatment for the prevention of a migraine during the double-blind period measured by Incidence of Unexpected Adverse Events.
- Responder rate in the nVNS group compared to the sham group
- Mean reduction in the number of headache days
- Mean reduction in days on which acute migraine medication
|
500 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03716505 |
GM-US-10 |
|
October 2018 |
February 2020 |
April 2020 |
October 23, 2018 |
October 23, 2018 |
|
- Summit Headache and Neurologic Institute, PC
Englewood, Colorado, United States - Montefiore Headache Center
Bronx, New York, United States
|
|
| 5 |
NCT03190044 |
Recruiting |
Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis |
|
- Dietary Supplement: PACR
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of Roma La Sapienza
- Gianluca Coppola
- Francesco Pierelli
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Prevention
|
- Migraine improvement in terms of responder rate
- Migraine improvement in terms of frequencies
|
82 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03190044 |
ParMig Study |
ParMig |
June 6, 2017 |
December 30, 2019 |
December 31, 2019 |
June 16, 2017 |
December 11, 2018 |
|
- Policlinico Umberto I
Rome, Italy
|
|
| 6 |
NCT02791997 |
Recruiting |
Audition After a Lesion and in Migraine. (AuditionPostLesion) |
- Migraine Disorders, Brain
|
- Other: Neuropsychological tests
- Other: Neurophysiological tests
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Percentages of correct responses in Neuropsychological tests
- reaction times in Neuropsychological tests
- Event-Related Potentials (EEG) in Neurophysiological tests
- Event-Related Fields (MEG) in Neurophysiological tests
|
335 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02791997 |
69HCL14_0202
2014-A01289-38 |
|
February 6, 2015 |
February 6, 2021 |
February 6, 2021 |
June 7, 2016 |
December 10, 2018 |
|
- Unité 201, Hôpital Neurologique
Bron, France - Service Explorations Fonctionnelles Neurologiques, Hôpital de la Croix-Rousse
Lyon, France
|
|
| 7 |
NCT02748577 |
Recruiting |
Pain Processing in Adults With Migraines |
|
- Other: Questionnaires
- Other: Quantitative Sensory Testing (QST) Pain Measurements
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Heat Pain Intensity coefficient and intercept from stimulus response curve
- Heat Pain Unpleasantness coefficient and intercept from stimulus response curve
- Pain Catastophizing score
- (and 13 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02748577 |
IRB00027845 |
|
January 2016 |
July 2020 |
July 2020 |
April 22, 2016 |
November 14, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 8 |
NCT03333109 |
Recruiting |
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients |
|
- Biological: Erenumab
- Other: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from baseline in monthly migraine days at the last month (Month 3) of the double-blind treatment period (DBTP)
- Achievement of at least a 50% reduction from baseline in monthly migraine days at Month 3
- Change from Baseline in acute migraine-specific medication treatment days at Month 3
- Change from Baseline in headache impact scores as measured by the HIT-6 at Month 3
|
880 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03333109 |
CAMG334A2302 |
EMPOwER |
February 8, 2018 |
February 7, 2020 |
February 7, 2020 |
November 6, 2017 |
November 29, 2018 |
|
- Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Buenos Aires, Argentina - (and 73 more...)
|
|
| 9 |
NCT03507400 |
Recruiting |
Introvision for Migraine and Headaches |
|
- Behavioral: Introvision: mental and emotional self-regulation
|
Interventional
|
Not Applicable |
- Ludwig-Maximilians - University of Munich
- University of Hamburg
- Introvision e.V
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of headache days per month
- Headache intensity
- acute medication per month
- (and 4 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03507400 |
IntroMig 632-15 |
IntroMig |
September 20, 2017 |
May 2019 |
May 2019 |
April 25, 2018 |
April 25, 2018 |
|
- Hospital of the Ludwig-Maximilians-University
Munich, Bavaria, Germany
|
|
| 10 |
NCT03689361 |
Not yet recruiting |
Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase. |
|
- Combination Product: MRI
- Diagnostic Test: MRI control
- Other: telephone consultation
|
Interventional
|
Phase 4 |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- frequency of the presence of visible brain vein abnormalities
- perfusion parameters
- asymmetry of visualization of the 3 intracranial arteries
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT03689361 |
RC31/16/8249
2017-004091-60 |
MARIE |
December 2018 |
December 2019 |
March 2020 |
September 28, 2018 |
September 28, 2018 |
|
- Hôpital Pierre Paul Riquet - CHU de Toulouse
Toulouse, France
|
|
| 11 |
NCT03773562 |
Not yet recruiting
New |
Imaging the Migraine Brain Pre- and Post-Erenumab |
|
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in Pain-Induced Brain Activations
- Changes in Brain Functional Connectivity (temporal correlations in BOLD signal fluctuations)
- Accuracy of Predicting Treatment Response
- (and 6 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03773562 |
18-001497 |
|
January 1, 2019 |
September 3, 2020 |
December 2, 2020 |
December 12, 2018 |
December 12, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
|
|
| 12 |
NCT02964741 |
Recruiting |
Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo) |
|
- Device: Active Comparator
- Device: Sham Comparator
|
Interventional
|
Not Applicable |
- University of Michigan
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain intensity level measured by the Visual Analog Scale in migraineurs (active or sham)
- Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs during sustained thermal pain threshold stress challenge subsequent to treatment by HD-tDCS (active or sham).
- Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs at rest subsequent to treatment by HD-tDCS (active or sham).
|
90 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02964741 |
HUM00107286
R01NS094413 |
|
February 22, 2017 |
April 2020 |
June 2020 |
November 16, 2016 |
August 14, 2018 |
|
- University of Michigan School of Dentistry
Ann Arbor, Michigan, United States
|
|
| 13 |
NCT03414203 |
Recruiting |
Comparison Between Transcranial Stimulation Protocols With Continuous Current in the Chronic Migraine |
|
|
Interventional
|
Not Applicable |
- Federal University of Paraíba
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment - MIDAS
- Headache Impact Test - HIT-6
- Wechsler Intelligence Scale Letters
- (and 10 more...)
|
45 |
Female |
20 Years to 45 Years (Adult) |
NCT03414203 |
NEUROMIG |
NEUROMIG |
August 14, 2017 |
February 5, 2018 |
April 16, 2018 |
January 29, 2018 |
January 29, 2018 |
|
- Federal University of Paraiba
João Pessoa, Paraiba, Brazil
|
|
| 14 |
NCT03670810 |
Not yet recruiting |
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks |
|
- Drug: Lasmiditan
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants that are Pain Free 2 Hours Postdose during the First Attack
- Percentage of Participants that are Pain Free at 2 Hours Postdose in at Least 2 out of 3 Attacks
- Percentage of Participants Very Much or Much Better as Measured by Patient Global Impression of Change (PGI-C), at 2 Hours Postdose During the First Attack
- (and 14 more...)
|
1600 |
All |
18 Years and older (Adult, Older Adult) |
NCT03670810 |
17131
H8H-MC-LAIJ
2018-001661-17 |
|
May 17, 2019 |
March 1, 2020 |
March 2, 2021 |
September 14, 2018 |
December 4, 2018 |
|
- Rehabilitation & Neurological Services LLC
Huntsville, Alabama, United States - Barrow Neurological Institute
Phoenix, Arizona, United States - UCSD Altman Clinical & Translational Research Institute (ACTRI)
La Jolla, California, United States - (and 141 more...)
|
|
| 15 |
NCT03152305 |
Recruiting |
Intracranial Pressure During Migraine |
|
- Other: Intracranial pressure variations
|
Observational
|
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Intracranial pressure variations
- Relationships between ICP variations and clinical parameters
- Relationships between ICP variations and pain relief
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT03152305 |
CHU-331
2014-A00042-45 |
MigICP |
July 21, 2014 |
May 2017 |
July 2018 |
May 15, 2017 |
May 15, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
|
| 16 |
NCT03732638 |
Recruiting |
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults |
|
- Drug: Rimegepant
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean number of migraine days per month
- Achievement of at least a 50% reduction from baseline in mean monthly migraine days.
- The mean number of rescue medication days per month.
- (and 4 more...)
|
1200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03732638 |
BHV3000-305 |
|
November 14, 2018 |
September 30, 2019 |
February 15, 2020 |
November 6, 2018 |
December 10, 2018 |
|
- MedPharmics, LLC
Phoenix, Arizona, United States - Tucson Neuroscience Research
Tucson, Arizona, United States - Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - (and 72 more...)
|
|
| 17 |
NCT03150797 |
Recruiting |
Melatonin for Adolescent Migraine Prevention Study |
|
- Drug: Melatonin
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2 |
- Amy Gelfand
- University of California, Los Angeles
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo.
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo.
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo.
- (and 6 more...)
|
210 |
All |
10 Years to 17 Years (Child) |
NCT03150797 |
16-19623 |
MAP |
August 2, 2017 |
June 2021 |
June 2021 |
May 12, 2017 |
October 16, 2018 |
|
- UCLA Headache Research and Treatment Program
Los Angeles, California, United States - University of California, San Francisco, (UCSF)
San Francisco, California, United States
|
|
| 18 |
NCT02695498 |
Recruiting |
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines |
|
- Other: Mindfulness Based Stress Reduction
- Other: Migraine/stress Education
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in frequency of migraine days from baseline
- Change in migraine duration from baseline
- Change in migraine severity-pain intensity from baseline
- (and 22 more...)
|
98 |
All |
18 Years and older (Adult, Older Adult) |
NCT02695498 |
K23AT008406 |
|
March 2016 |
May 2019 |
June 2019 |
March 1, 2016 |
November 14, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States - Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 19 |
NCT03461874 |
Recruiting |
ACT Therapy for HF Migraine |
|
- Behavioral: Education of patients
- Behavioral: ACT
- Drug: Pharmacological prophylaxis
|
Interventional
|
Not Applicable |
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Brigham and Women's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction of headaches frequency
- Difference in the proportion of patients achieving the reduction of 50% or more of days with headache compared to baseline
- Medications intake
- (and 10 more...)
|
64 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03461874 |
ACT protocol |
ACTMigraine |
March 15, 2018 |
July 15, 2019 |
July 15, 2021 |
March 12, 2018 |
September 14, 2018 |
|
- Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit
Milano, Italy
|
|
| 20 |
NCT03556722 |
Not yet recruiting |
Migraine Reduction Study Using Repetitive Transcranial Stimulation |
|
- Device: Repetitive Transcranial Magnetic Stimulation.
- Device: Sham rTMS
|
Interventional
|
Not Applicable |
- Universiti Putra Malaysia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline headache frequency at 3 months
- Change from baseline headache severity by Visual Analogue Scale (VAS) at 3 months
- Changes of transcranial Doppler (TCD) parameters in migraine patients in response to rTMS.
- (and 8 more...)
|
200 |
All |
18 Years to 45 Years (Adult) |
NCT03556722 |
GPB/2017/9585500 |
MRSTIMAS |
December 2018 |
December 2019 |
June 2020 |
June 14, 2018 |
October 23, 2018 |
|
- University Putra Malaysia
Serdang, Selangor, Malaysia
|
|
| 21 |
NCT02582996 |
Not yet recruiting |
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks |
|
- Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
- Drug: Acetaminophen
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain relief of Cefalium® compared to Tylenol®
- Pain decrease after use of investigational product, without a rescue medication
- Pain decrease after use of the investigational product, without a rescue medication
- (and 4 more...)
|
336 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02582996 |
ACH-CFL-03(01/14) |
|
April 2019 |
April 2020 |
June 2020 |
October 21, 2015 |
April 12, 2018 |
|
- Centro de Pesquisa Clínica - CPEC / Associação Obras Sociais Irmã Dulce
Salvador, Bahia, Brazil - Centro de Pesquisa Clínica Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande Do Sul, Brazil - Centro de Desenvolvimento em Estudos Clínicos Brasil - CDEC Brasil
São Paulo, Brazil - (and 3 more...)
|
|
| 22 |
NCT03275922 |
Recruiting |
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE |
|
- Drug: Placebo ZNS
- Drug: ZNS
|
Interventional
|
Phase 3 |
- IMPAX Laboratories, Inc.
- AstraZeneca
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain-free status at 2 hours post treatment
- Proportion of subjects who achieve pain-free status at 24 hours post-dose
- Headache response at 24 hours post-dose
- Sustained headache response at 24 hours post-dose
|
426 |
All |
6 Years to 11 Years (Child) |
NCT03275922 |
IPX229-B16-01 |
|
December 4, 2017 |
April 2020 |
May 2020 |
September 8, 2017 |
October 31, 2018 |
|
- Arkansas Children's Hospital (109)
Little Rock, Arkansas, United States - Advanced Research Center, Inc (134)
Anaheim, California, United States - Sierra Medical Research (124)
Fresno, California, United States - (and 38 more...)
|
|
| 23 |
NCT02945839 |
Not yet recruiting |
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department |
|
- Drug: Preventative Medication (PM)
- Behavioral: Enhanced Usual Care
- Behavioral: PMR (progressive muscle relaxation therapy)
|
Interventional
|
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline
- Perceived Stress Scale (PSS)
- Number of days/week treated with acute medications
- Number of drug administrations/week for acute medications
|
90 |
All |
18 Years to 64 Years (Adult) |
NCT02945839 |
16-00548 |
|
December 2018 |
December 2018 |
December 2018 |
October 26, 2016 |
May 31, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 24 |
NCT03597529 |
Recruiting |
CHOCOlate MeLatonin for AdolescenT MigrainE |
|
|
Interventional
|
Phase 2 |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
100 |
All |
3 Years to 17 Years (Child) |
NCT03597529 |
17-22645 |
CHOCOLATE |
September 25, 2017 |
September 1, 2021 |
September 1, 2022 |
July 24, 2018 |
July 24, 2018 |
|
- University of California, San Francisco, (UCSF)
San Francisco, California, United States
|
|
| 25 |
NCT03081390 |
Recruiting |
Migraine and CVD Risk in Women |
|
- Other: Mixed meal tolerance testing
- Other: Skin conductance & cold pressor test
- Other: Flow-mediated dilation testing
|
Interventional
|
Not Applicable |
- University of Pennsylvania
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- LPS area under the curve (AUC)
- Flow-mediated dilation (FMD)
- Sympathetic tone at rest and with painful stimulus
|
30 |
Female |
18 Years to 35 Years (Adult) |
NCT03081390 |
826251 |
|
April 1, 2017 |
March 2019 |
March 2020 |
March 16, 2017 |
October 25, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 26 |
NCT03742024 |
Not yet recruiting
New |
Study of Pediatric Migraine: The Pediatric Migraine Registry |
|
|
Observational
|
|
- Duke University
- University of California, San Francisco
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
200 |
All |
4 Years to 17 Years (Child) |
NCT03742024 |
Pro00100205 |
|
December 1, 2018 |
May 1, 2021 |
May 1, 2021 |
November 15, 2018 |
November 15, 2018 |
|
|
|
| 27 |
NCT03706794 |
Not yet recruiting |
Clinical Decision Support for Patient Migraine Management |
|
- Behavioral: Clinical Decision Support Tool
- Behavioral: Headache Education
|
Interventional
|
Not Applicable |
- Albert Einstein College of Medicine, Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Adherence to Acute Migraine Management Strategies: Treat Early
- Adherence to Acute Migraine Management Strategies: Avoid Overuse
- Adherence to Preventive Behavioral Strategies
- (and 6 more...)
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03706794 |
2015-5743
1K23NS096107-01 |
CDST |
October 2018 |
April 2020 |
April 2021 |
October 16, 2018 |
October 16, 2018 |
|
|
|
| 28 |
NCT03167060 |
Recruiting |
BrainCool-Migraine Intranasal Cooling Trial |
|
- Device: Active RhinoChill
- Device: Control Rhinochill
|
Interventional
|
Not Applicable |
- Cumbria Partnership NHS Foundation Trust
- BrainCool AB
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Participant is pain free at two hours following trial device treatment The patients' first treatment will be used for analysis of the superiority of the rate of patients pain free at two hours following treatment for those receiving the standard R
- Percentage of patients pain free immediately after treatment (10 minutes), at 1 hour, and 24 hours following treatment
- Headache response
- (and 3 more...)
|
90 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03167060 |
CP1628 |
|
May 8, 2017 |
September 30, 2018 |
November 30, 2018 |
May 25, 2017 |
November 8, 2017 |
|
- Neurosciences department, Penrith Hospital, Cumbria Partnership NHS Foundation Trust
Penrith, Cumbria, United Kingdom - South tees Hospital
Middlesbrough, United Kingdom - The Newcastle upon Tyne Hospitals
Newcastle upon Tyne, United Kingdom - City Hospital, Sunderland, UK
Sunderland, United Kingdom
|
|
| 29 |
NCT03481400 |
Recruiting |
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment |
|
- Drug: Calcitonin Gene-Related Peptide
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Incidence of migraine
- Area under the curve of headache intensity
- Heart rate
- Blood pressure
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03481400 |
H-16014580 |
|
July 2016 |
September 2019 |
September 2019 |
March 29, 2018 |
March 29, 2018 |
|
- Danish Headache Center, Rigshospitalet Glostrup
Copenhagen, Glostrup, Denmark
|
|
| 30 |
NCT03592329 |
Not yet recruiting |
Vagus Nerve Stimulation and Stress Reduction Training for Migraine |
|
- Behavioral: Stress Reduction Training A
- Device: active tVNS
- Behavioral: Stress Reduction Training B
- Device: sham tVNS
|
Interventional
|
Early Phase 1 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Brain activity changes in migraine patients in response to treatment
- Brain inflammation changes in migraine patients in response to treatment
- Brain activity differences between Migraine patients and healthy controls
- Brain inflammation differences between Migraine patients and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03592329 |
P01AT009965 |
|
February 2019 |
July 2023 |
July 2023 |
July 19, 2018 |
July 19, 2018 |
|
- Anthinoula A. Martinos Center
Charlestown, Massachusetts, United States
|
|
| 31 |
NCT03404336 |
Recruiting |
Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy |
|
- Behavioral: Well-Being Therapy
- Other: Control condition
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- disability due to migraine
- frequency of migraine attacks
- duration of migraine attacks
- (and 4 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03404336 |
WBT in MIG |
|
October 1, 2018 |
May 30, 2019 |
May 30, 2019 |
January 19, 2018 |
October 11, 2018 |
|
- Fiammetta COSCI
Florence, Italy - Centro Cefalee e Farmacologia Clinica
Florence, Italy
|
|
| 32 |
NCT03494673 |
Recruiting |
Prediction of WMH in Migraine Using a BOLD-CVR Map |
|
- Diagnostic Test: BOLD MRI
|
Observational
|
|
- Samsung Medical Center
- National Research Foundation of Korea
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- CVR association with WMH development
- Spatial pattern of CVR
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03494673 |
2017-04-049 |
|
July 13, 2018 |
February 28, 2019 |
February 28, 2020 |
April 11, 2018 |
October 9, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 33 |
NCT03499119 |
Recruiting |
AMG 334 20160172 Pediatric Migraine PK Study. |
|
- Drug: AMG 334 Dose 1
- Drug: AMG 334 Dose 2
- Drug: AMG 334 Dose 3
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Serum PK parameter of AMG 334 time to maximum observed concentration [Cmax]
- Serum PK parameter of AMG 334 time to maximum concentration [tmax]
- Serum PK parameter of AMG 334 area under the concentration time cure from 0 to 28 days [AUC 0-28days]
- (and 11 more...)
|
60 |
All |
6 Years to 17 Years (Child) |
NCT03499119 |
20160172 |
|
May 4, 2018 |
December 16, 2020 |
September 21, 2021 |
April 17, 2018 |
October 15, 2018 |
|
- Research Site
Little Rock, Arkansas, United States - Research Site
West Palm Beach, Florida, United States - Research Site
Atlanta, Georgia, United States - (and 2 more...)
|
|
| 34 |
NCT03504150 |
Recruiting |
Testing myWHI: Online Self-help Programs for Headaches |
|
- Behavioral: SPHERE
- Behavioral: PRISM
|
Interventional
|
Not Applicable |
- IWK Health Centre
- Nova Scotia Health Research Foundation
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinically significant improvement (50% reduction or greater) in number of headache days in a 4-week period from baseline to 4-months post-randomization
- Statistically significant improvement in peak headache severity in a 4-week period from baseline to 4-months post-randomization
- Statistically significant improvement in headache-related functional impairment from baseline to 4-months post-randomization
- (and 2 more...)
|
424 |
All |
14 Years to 40 Years (Child, Adult) |
NCT03504150 |
1022640 |
|
May 4, 2018 |
October 1, 2019 |
May 1, 2020 |
April 20, 2018 |
October 16, 2018 |
|
- IWK Health Centre
Halifax, Nova Scotia, Canada
|
|
| 35 |
NCT03772860 |
Not yet recruiting
New |
Defining the Sympathetic Skin Response of Migraineurs in the Facial Area |
|
- Other: Pain stimulation
- Other: Visual stimulation
- Other: Auditory stimulation
- Other: Mental stress
|
Observational
|
|
- Hillel Yaffe Medical Center
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Defining sympathetic skin response in migraineurs
- Defining differences between sympathetic skin response in migraineurs
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03772860 |
HYMC-113-18 |
|
December 2018 |
December 2019 |
December 2019 |
December 11, 2018 |
December 11, 2018 |
|
- Hillel Yaffe Medical Center
Hadera, Israel
|
|
| 36 |
NCT03559257 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days in Participants with Episodic Migraine
- Percentage of Participants with ≥50% Reduction from Baseline in Monthly Migraine Headache Days
- (and 10 more...)
|
420 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03559257 |
16670
I5Q-MC-CGAW
2018-000600-42 |
CONQUER |
July 31, 2018 |
July 10, 2019 |
October 31, 2019 |
June 18, 2018 |
December 4, 2018 |
|
- 21st Century Neurology
Phoenix, Arizona, United States - Medical Center for Clinical Research
San Diego, California, United States - California Medical Clinic for Headache
Santa Monica, California, United States - (and 77 more...)
|
|
| 37 |
NCT02315833 |
Recruiting |
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients |
|
- Drug: Acetium
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Biohit Oyj
- The Finnish Funding Agency for Technology and Innovation (TEKES)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of migraine attacks (NMA) per evaluation interval
- Number of migraine days (NMD) per evaluation period
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02315833 |
AC-MIGPREV-1 |
|
June 2014 |
February 2019 |
February 2019 |
December 12, 2014 |
September 24, 2018 |
|
- Confido Privat Medical Clinic
Tallinn, Estonia - Tartu University Hospital, Neurology Clinic
Tartu, Estonia - Terveystalo, Kamppi
Helsinki, Finland - (and 4 more...)
|
|
| 38 |
NCT03559088 |
Recruiting |
A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care |
|
|
Interventional
|
Not Applicable |
- Eli Lilly and Company
- Atrium Health
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Number of Participants Receiving a Preventive Migraine Prescription
- Number of Months of App Use
- Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates
- (and 6 more...)
|
200 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03559088 |
17129
I5Q-MC-CGBA |
|
June 11, 2018 |
July 18, 2019 |
July 18, 2020 |
June 15, 2018 |
December 4, 2018 |
|
- Charlotte Internal Medicine
Charlotte, North Carolina, United States - Charlotte Medical Clinic
Charlotte, North Carolina, United States - Carmel Family Physicians
Charlotte, North Carolina, United States - (and 4 more...)
|
|
| 39 |
NCT03459495 |
Not yet recruiting |
Therapeutic Ultrasound in the Treatment of Migraine |
|
- Device: therapeutic ultrasound
- Device: placebo ultrasound
|
Interventional
|
Not Applicable |
- Bursa Yüksek İhtisas Education and Research Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Numeric rating scale (NRS)
- Migraine Disability Assessment Questionnaire Score (MIDAS)
- paracetamol consumption
- the number of migraine attacks per month.
|
58 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03459495 |
2011-KAEK-2018-1/25 |
|
March 10, 2018 |
September 10, 2018 |
September 10, 2018 |
March 9, 2018 |
March 9, 2018 |
|
|
|
| 40 |
NCT02681211 |
Recruiting |
Auricular Acupuncture vs SOC in Migraine HA |
|
- Other: Auricular Acupuncture
- Drug: Ketorolac 0.5mg/kg, max 30mg
- Drug: Metoclopramide 0.1 mg/kg, max 10mg
- (and 2 more...)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in baseline pain score by a numerical self-reported visual analog pain score (VAS)
- Duration of pain relief using the VAS pain scale
|
80 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02681211 |
15.0827 |
MigAcu |
February 2016 |
December 2018 |
June 2019 |
February 12, 2016 |
June 8, 2018 |
|
- Norton Children's Hospital
Louisville, Kentucky, United States - Norton Children's Medical Center
Louisville, Kentucky, United States
|
|
| 41 |
NCT03099070 |
Recruiting |
Acute Stress Response in Migraine Sufferers |
|
- Behavioral: Stress
- Other: Fasting
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Headache/Medication Use
- Time to next headache attack
- Medication use
- Pain Scores
|
212 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03099070 |
2016P001834 |
|
March 8, 2017 |
May 31, 2020 |
May 31, 2020 |
April 4, 2017 |
April 4, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 42 |
NCT03263897 |
Recruiting |
Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief |
|
- Device: insufflation
- Device: placebo insufflation
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Changes in Symptoms severity scale
- Changes in pain level
- Changes in Symptoms severity scale at 2 hours
- (and 3 more...)
|
50 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03263897 |
CI-IRB-20170814001 |
|
August 21, 2017 |
August 2018 |
April 2019 |
August 28, 2017 |
April 26, 2018 |
|
- YRMC: Physiatry, Neurosurgery, Neurology Clinic
Prescott, Arizona, United States - FNOR Clinic Scottsdale
Scottsdale, Arizona, United States
|
|
| 43 |
NCT03488563 |
Recruiting |
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine |
|
- Biological: B244
- Biological: Vehicle
|
Interventional
|
Phase 2 |
- AOBiome LLC
- Veristat, Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Mean change in monthly migraine days.
- Mean change in monthly migraine attacks.
- (and 5 more...)
|
303 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03488563 |
MGB244-001 |
|
March 30, 2018 |
February 20, 2019 |
February 20, 2019 |
April 5, 2018 |
December 11, 2018 |
|
- Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - Collaborative Neuroscience Network, LLC
Long Beach, California, United States - CI Trials
Riverside, California, United States - (and 19 more...)
|
|
| 44 |
NCT03159000 |
Recruiting |
A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks |
|
- Drug: Saline
- Combination Product: lidocaine/bupivacaine
|
Interventional
|
Phase 4 |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of subjects experiencing headache improvement at 2 hours
- Percentage of subjects experiencing headache improvement 10 minutes
- Percentage of subjects experiencing headache improvement at 30 minutes
- (and 7 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03159000 |
GON/WBY/003 |
|
May 1, 2017 |
December 31, 2017 |
June 30, 2018 |
May 18, 2017 |
May 18, 2017 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 45 |
NCT03083860 |
Not yet recruiting |
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. |
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Evaluation of correlation of attention-related electrophysiological changes and patients' migraine dynamics based at-home EEG measurements via mobile phone app.
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03083860 |
CLD10 |
|
September 2017 |
April 2018 |
December 2018 |
March 20, 2017 |
June 16, 2017 |
|
|
|
| 46 |
NCT03303105 |
Recruiting |
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine |
|
|
Interventional
|
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Adverse Events
- Mean change from baseline in the number of migraine days
- Mean change from baseline in the monthly average of migraine days
- (and 2 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303105 |
406-102-00003
JapicCTI-173726 |
|
January 4, 2018 |
February 2020 |
February 2020 |
October 5, 2017 |
February 16, 2018 |
|
|
|
| 47 |
NCT03453203 |
Not yet recruiting |
Treatment of Cervical Pain in Chronic Migraine |
|
- Other: Osteopathic Manipulative Treatment Using Counterstrain
|
Interventional
|
Not Applicable |
- University Hospitals Cleveland Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Treatment of Cervical Pain in Chronic Migraine
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03453203 |
UHClevelandMC1 |
|
April 29, 2018 |
December 29, 2018 |
December 29, 2018 |
March 5, 2018 |
March 7, 2018 |
|
|
|
| 48 |
NCT03303079 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine |
|
- Drug: TEV-48125
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12-week period after the first dose of Interventional Medicinal Product(IMP)
- Proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications
- (and 2 more...)
|
540 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303079 |
406-102-00001
JapicCTI-173723 |
|
December 19, 2017 |
June 2019 |
June 2019 |
October 5, 2017 |
December 11, 2018 |
|
|
|
| 49 |
NCT03303092 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine |
|
- Drug: TEV-48125
- Drug: Placebos
|
Interventional
|
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of migraine days during the 12-week period after the first dose of Interventional Medicinal Product
- Proportion of patients reaching at least 50% reduction in the monthly average number of migraine days
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications relative to baseline
- Mean change from baseline in the number of migraine days
|
330 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303092 |
406-102-00002
JapicCTI-173725 |
|
December 19, 2017 |
June 2019 |
June 2019 |
October 5, 2017 |
December 11, 2018 |
|
|
|
| 50 |
NCT02725554 |
Not yet recruiting |
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine |
|
- Device: StimRelieve Halo System
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Headache Days
- Adverse Events
- Migraine Days
- (and 2 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT02725554 |
30-00070 |
|
January 2019 |
December 2020 |
December 2021 |
April 1, 2016 |
April 19, 2018 |
|
|
|
| 51 |
NCT02583581 |
Recruiting |
Evaluation of Use of Brain Activity Monitoring for Prediction of Migraine Attacks |
|
- Device: EEG monitoring (MindWave by NeuroSky)
- Device: EEG monitoring (EPOC by Emotiv)
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Measurements of brain electrical signal in Micro volt.
|
50 |
All |
18 Years to 50 Years (Adult) |
NCT02583581 |
CLD4 |
|
October 2015 |
January 2018 |
February 2018 |
October 22, 2015 |
June 16, 2017 |
|
- Rambam Medical Center
Haifa, Israel
|
|
| 52 |
NCT03395457 |
Recruiting |
Tertiary Care With or Without Manual Therapy for Chronic Migraine |
|
- Drug: Care as usual
- Other: Manual Therapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in migraine-related disability
- Change in Migraine Specific Quality of Life Questionnaire Score (MSQoL 2.1)
- Headache Frequency
|
70 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03395457 |
Bournemouth 228901 |
|
August 3, 2018 |
December 1, 2018 |
December 1, 2018 |
January 10, 2018 |
September 27, 2018 |
|
- Salford Royal NHS Foundation Trust
Manchester, United Kingdom
|
|
| 53 |
NCT03526874 |
Not yet recruiting |
Occipital Blocks for Acute Migraine |
- Chronic Migraine, Headache
- Episodic Migraine
|
- Drug: Lidocaine 4% Topical Application Cream [LMX 4]
- Drug: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
- Drug: Normal Saline
|
Interventional
|
Phase 3 |
- Children's Hospital of Philadelphia
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change in Pain Intensity Scores
- Change from Baseline Disability
- Percentage of Subjects with Pain Freedom
- (and 3 more...)
|
58 |
All |
7 Years to 17 Years (Child) |
NCT03526874 |
18-014939 |
|
November 2018 |
November 2021 |
December 2021 |
May 16, 2018 |
October 24, 2018 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 54 |
NCT03432286 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the Number of Monthly Migraine Headache Days
- Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days
- Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting
- (and 13 more...)
|
645 |
All |
6 Years to 17 Years (Child) |
NCT03432286 |
16352
I5Q-MC-CGAS
2017-004351-23 |
REBUILD |
March 14, 2018 |
May 31, 2021 |
June 25, 2022 |
February 14, 2018 |
December 4, 2018 |
|
- Medical Center for Clinical Research
San Diego, California, United States - Clinical Neuroscience Solutions Inc
Jacksonville, Florida, United States - Sensible Healthcare
Ocoee, Florida, United States - (and 14 more...)
|
|
| 55 |
NCT03763058 |
Not yet recruiting
New |
Music Intervention on Migraine Headaches |
|
|
Interventional
|
Not Applicable |
- Association de Musicothérapie Applications et Recherches Cliniques
- Centre Hospitalier Universitaire de la Réunion
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of migraine attacks (number of days per month)
- Duration of migraine attacks (hours)
- Intensity of migraine attacks
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03763058 |
MusicMig |
CHU |
December 2018 |
February 2019 |
February 2019 |
December 4, 2018 |
December 4, 2018 |
|
- CHU de la Réunion
Saint-Pierre, Réunion
|
|
| 56 |
NCT02706015 |
Not yet recruiting |
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks |
|
- Drug: Cefaliv® & Placebo
- Drug: Neosaldina® & Placebo
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Evaluate the efficacy and non-inferiority of Cefaliv® compared to Neosaldina® in pain relief
- The remission of the pain after use of the investigational product, without use of a rescue medication;
- The relief of pain after use of the investigational product, without use of a rescue medication;
- (and 3 more...)
|
216 |
All |
18 Years to 66 Years (Adult, Older Adult) |
NCT02706015 |
ACH-CFL-03(10/14) |
|
October 2020 |
May 2021 |
July 2021 |
March 11, 2016 |
April 9, 2018 |
|
- Ache Laboratorios Farmaceuticos
Guarulhos, São Paulo, Brazil
|
|
| 57 |
NCT03576820 |
Not yet recruiting |
Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department |
|
- Drug: Lidocaine
- Drug: Placebo
|
Interventional
|
Phase 3 |
- New York City Health and Hospitals Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Pain Score
- The Number of Subjects with Improvement of Associated Symptoms
- The Number of Subjects Who Receive IV Pain Medications
- (and 3 more...)
|
50 |
All |
10 Years to 20 Years (Child, Adult) |
NCT03576820 |
2018-9278 |
|
August 2018 |
August 2019 |
December 2019 |
July 3, 2018 |
July 6, 2018 |
|
- Jacobi Medical Center
Bronx, New York, United States
|
|
| 58 |
NCT03700320 |
Recruiting |
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine |
|
- Drug: Atogepant 60 mg
- Drug: Standard of Care (SOC) Migraine Prevention Medication
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with at Least 1 Treatment Emergent Adverse Event
- Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Urinalysis) as assessed by the Investigator
- Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as assessed by the Investigator
- (and 2 more...)
|
700 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03700320 |
3101-302-002 |
|
October 8, 2018 |
June 22, 2020 |
November 9, 2020 |
October 9, 2018 |
November 29, 2018 |
|
- Simon Williamson Clinic
Birmingham, Alabama, United States - Achieve Clinical Research, LLC
Birmingham, Alabama, United States - East Valley Family Physicians
Chandler, Arizona, United States - (and 111 more...)
|
|
| 59 |
NCT03400059 |
Recruiting |
Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine |
|
- Device: Chordate System S211 in treatment mode
- Device: Chordate System S211 in placebo mode
|
Interventional
|
Not Applicable |
- Chordate Medical
- Vinnova (Swedish Governmental Agency for Innovation Systems)
- FGK Clinical Research GmbH
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Mean change from Baseline (4-week screening period) in monthly headache days with moderate to severe intensity in 4-week performance assessment period (V3 to V7).
- Mean change from Baseline in monthly headache days with moderate to severe intensity in follow-up period
- Mean change from Baseline in monthly migraine days
- (and 8 more...)
|
140 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03400059 |
PM007 |
|
March 22, 2018 |
July 2019 |
July 2019 |
January 17, 2018 |
November 19, 2018 |
|
- Neurologie- & Kopfschmerzzentrum
München, Bayern, Germany - Klinikum Großhadern / Neurologische Klinik der Universität München
München, Bayern, Germany - Migräne-Klinik Königstein
Königstein Im Taunus, Hessen, Germany - (and 2 more...)
|
|
| 60 |
NCT02765581 |
Recruiting |
Efficacy Study of Acupuncture in the Prevention of Migraine Without Aura |
|
- Device: Verum acupuncture
- Device: Sham acupuncture
- Behavioral: Usual care
|
Interventional
|
Not Applicable |
- Wei Wang
- Hubei College of Traditional Chinese Medicine
- Hubei Hospital of Traditional Chinese Medicine
- (and 6 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the number of migraine days
- Change in the frequency of migraine attacks
- The proportion of responders
- (and 7 more...)
|
150 |
All |
15 Years to 65 Years (Child, Adult, Older Adult) |
NCT02765581 |
201403RCTMWA |
|
May 1, 2016 |
December 31, 2018 |
June 30, 2019 |
May 6, 2016 |
June 1, 2018 |
|
- Department of Neurology of Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
|
| 61 |
NCT03338920 |
Recruiting |
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents |
- Acute Migraine With or Without Aura
|
- Drug: sumatriptan nasal powder
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants who were headache pain free at 120 minutes after treatment
- Number of participants with headache relief at 120 minutes after treatment
- Number of participants who were headache pain free any time after treatment
- (and 9 more...)
|
420 |
All |
12 Years to 17 Years (Child) |
NCT03338920 |
17-AVP-825-301 |
|
November 2, 2017 |
November 2019 |
November 2019 |
November 9, 2017 |
July 11, 2018 |
|
- Phoenix Children's Hospital
Phoenix, Arizona, United States - Fullerton Neurology and Headache Center
Fullerton, California, United States - Alpine Clinical Research Center, Inc.
Boulder, Colorado, United States - (and 24 more...)
|
|
| 62 |
NCT02358681 |
Recruiting |
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children |
|
- Drug: Ketorolac, intranasal
- Drug: Ketorolac, intravenous
- Drug: Placebo, intravenous
- Drug: Placebo, intranasal
|
Interventional
|
Phase 3 |
- Columbia University
- Migraine Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain score after analgesic administration (Faces Pain Scale - Revised (FPS-R)
- Time to achieve clinically significant reduction in pain after analgesic administration (Pain score)
|
80 |
All |
8 Years to 17 Years (Child) |
NCT02358681 |
AAAO1302 |
|
May 2015 |
December 2019 |
December 2019 |
February 9, 2015 |
April 10, 2018 |
|
- NewYork Presbyterian Morgan Stanley Children's Hospital
New York, New York, United States
|
|
| 63 |
NCT03598075 |
Recruiting |
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients |
|
- Other: Amylin (Pramlintide)
- Other: CGRP
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Headache intensity
- Headache characteristics
- Dilatation of Arteria radialis and arteria temporalis superficialis
- (and 2 more...)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT03598075 |
H-17035931 |
|
July 1, 2018 |
July 1, 2019 |
July 1, 2019 |
July 25, 2018 |
August 7, 2018 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 64 |
NCT02795351 |
Recruiting |
Induction of Migraine Aura With Sildenafil |
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aura and migraine like headache
- Markers of endothelial function in blood
- Migraine without aura
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT02795351 |
H-15008491 |
|
June 2015 |
March 2019 |
March 2019 |
June 10, 2016 |
October 23, 2018 |
|
- Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
|
|
| 65 |
NCT03220113 |
Recruiting |
Treatment of Chronic Migraine Headaches. |
- Chronic Migraine Without Aura, Intractable
- Migraine With Typical Aura
- Migraine Disorders
|
- Combination Product: Dexamethasone, Lidocaine, Thiamine cohort
|
Interventional
|
Phase 1
Phase 2 |
- Corona Doctors Medical Clinics, Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of the safety to the De-Novo treatment formula in study patients
- Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure
|
100 |
All |
10 Years to 90 Years (Child, Adult, Older Adult) |
NCT03220113 |
2017/05/1 |
Migraine |
July 1, 2017 |
July 1, 2018 |
July 1, 2019 |
July 18, 2017 |
April 4, 2018 |
|
- Corona Doctors Medical Clinics Inc
Corona, California, United States
|
|
| 66 |
NCT03570086 |
Not yet recruiting |
Multiparametric Diagnostic Model of Thick-section Clinical-quality MRI Data in Detecting Migraine Without Aura |
|
- Diagnostic Test: diagnostic
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- accuracy
- sensitivity
- specificity
|
400 |
All |
21 Years to 55 Years (Adult) |
NCT03570086 |
20170908010418 |
|
July 1, 2018 |
December 30, 2018 |
December 30, 2019 |
June 26, 2018 |
June 26, 2018 |
|
- Xijing Hospital
Xi'an, Shaanxi, China
|
|
| 67 |
NCT03097536 |
Recruiting |
Migraine and Homeostasis:What Can we Learn From Glucose |
|
|
Interventional
|
Not Applicable |
- Beth Israel Deaconess Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The difference in blood glucose on days with migraine compared to blood glucose on days without migraine
- The primary outcome is the change in pain score from the time of pain plateau to the pain score at 120 minutes as measured by a visual analogue scale.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03097536 |
2015P000419 |
|
March 2016 |
June 2020 |
January 2021 |
March 31, 2017 |
June 4, 2018 |
|
- Beth Israel Deaconess Medial Center
Boston, Massachusetts, United States
|
|
| 68 |
NCT03543254 |
Recruiting |
"Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine |
- Migraine Disorders
- Chronic Disease
|
|
Interventional
|
Phase 2 |
- Norwegian University of Science and Technology
- St. Olavs Hospital
- Mayo Clinic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of adverse events
- moderate-severe headache days 5-8 weeks after injection compared with baseline
|
40 |
All |
18 Years to 64 Years (Adult) |
NCT03543254 |
2017/1490
2017-002516-13 |
|
June 1, 2018 |
May 2020 |
May 2020 |
June 1, 2018 |
June 12, 2018 |
|
- Mayo Clinic, 13400 E. Shea Blvd
Scottsdale, Arizona, United States - St Olavs Hospital
Trondheim, Norway
|
|
| 69 |
NCT03419715 |
Recruiting |
Topical Bimatoprost in the Treatment of Migraine |
- Migraine Disorders
- Headache Disorders
|
- Drug: Bimatoprost Topical Solution
- Drug: Control
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Reduction in Headache Frequency
- Intensity of Headaches
- Duration of Headaches
- Migraine Disability Assessment Scale (MIDAS)--Quality of Life
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03419715 |
17-MAN-001 |
|
January 5, 2018 |
December 2018 |
December 2018 |
February 2, 2018 |
September 19, 2018 |
|
- CTI Clinical Trial and Consulting Services
Cincinnati, Ohio, United States - Omega Medical Research
Warwick, Rhode Island, United States
|
|
| 70 |
NCT02120326 |
Recruiting |
Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine |
- Chronic Migraine as Defined by Criteria of International Headache Society (IHS)
|
- Device: Transcranial direct current stimulation of the motor cortex
- Device: simulation of Transcranial direct current stimulation of the motor cortex
|
Interventional
|
Not Applicable |
- University Hospital, Grenoble
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Comparison of the evolution of seizure frequency between the two groups
- Comparison of the evolution of seizure severity between the two groups
- Comparison of the evolution of crisis treatment use between the two groups
- (and 4 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02120326 |
DCIC13/48 |
Medis |
May 5, 2014 |
December 2018 |
December 2018 |
April 22, 2014 |
October 11, 2018 |
|
- Grenoble University Hospital
Grenoble, Isere, France - Hospital of Voiron
Voiron, Isere, France
|
|
| 71 |
NCT02903680 |
Recruiting |
RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED |
|
- Drug: Dexamethasone group
- Drug: Placebo group
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- incidence of relapse following discharge from the ED
- mean level of pain
- associated symptoms (i.e. nausea, vomiting, photophobia and sonophobia),
- (and 2 more...)
|
116 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02903680 |
3662 |
|
May 2014 |
May 2019 |
June 2019 |
September 16, 2016 |
October 20, 2017 |
|
- CHU Sainte Justine
Montréal, Quebec, Canada
|
|
| 72 |
NCT03026101 |
Recruiting |
Understanding the Pathophysiology of Migraine Pain |
- Migraine Disorders
- Migraine, Classic
- Migraine Without Aura
|
|
Interventional
|
Not Applicable |
- Montefiore Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Migraine
- Migraine log pre-procedure: severity measure
- Migraine log pre-procedure: frequency measure
- (and 17 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03026101 |
2017-8335 |
|
January 2017 |
January 2019 |
June 2019 |
January 20, 2017 |
April 24, 2018 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 73 |
NCT03698409 |
Not yet recruiting |
Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine. |
- Chronic Migraine, Headache
|
- Other: Preserved saline in reconstitution of Botox
|
Interventional
|
Phase 4 |
- State University of New York - Upstate Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Verbal Pain Scale
- Headache-day frequency
|
70 |
All |
18 Years to 79 Years (Adult, Older Adult) |
NCT03698409 |
1318956 |
B-RECON |
January 1, 2019 |
June 1, 2019 |
July 1, 2019 |
October 8, 2018 |
October 8, 2018 |
|
|
|
| 74 |
NCT03557333 |
Recruiting |
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP-301) |
|
- Combination Product: INP104
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serious treatment emergent adverse events (SAEs)
- Non-serious treatment emergent adverse events (AEs)
- Change in nasal mucosa
- Change in olfactory function
|
240 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03557333 |
INP104-301 |
|
July 13, 2018 |
October 18, 2019 |
October 18, 2019 |
June 15, 2018 |
December 7, 2018 |
|
- Synexus - Clinical Research Advantage, Inc. - Southview Medical Group, PC., 833 Saint Vincent's Drive, Suite 300
Birmingham, Alabama, United States - Synexus - Clinical Research Advantage, Inc. - Simon Williamson Clinical, PC., 832 Princeton Avenue Southwest
Birmingham, Alabama, United States - Alabama Clinical Therapeutics, LLC., 52 Medical Park East Drive, Suite 203
Birmingham, Alabama, United States - (and 35 more...)
|
|
| 75 |
NCT03701477 |
Not yet recruiting |
Trans-diagnostic Cognitive-behavioral Therapy for Treatment of Migraine |
|
- Behavioral: Trans-diagnostic cognitive-behavioral therapy
- Behavioral: General relaxation/stress management therapeutic session
|
Interventional
|
Not Applicable |
- Isfahan University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Visual Analog Scale
- Headache Impact Test-6 (HIT-6)
- Migraine Disability Assessment Scale (MIDAS)
- Hospital Anxiety and Depression Scale (HADS)
|
15 |
All |
20 Years to 50 Years (Adult) |
NCT03701477 |
18820701962055 |
|
October 2018 |
March 2019 |
April 2019 |
October 10, 2018 |
October 10, 2018 |
|
- Shoko0h counselling center
Isfahan, Iran, Islamic Republic of
|
|
| 76 |
NCT03578354 |
Not yet recruiting |
4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine |
- Vestibular Migraine
- Migraine Disorders
- Vestibular Diseases
|
- Drug: 4-aminopyridine
- Drug: Atenolol
- Other: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts Eye and Ear Infirmary
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Dizziness Handicap Score
- Change in number of dizziness episodes
- Change in motion sickness susceptibility
- (and 5 more...)
|
219 |
All |
18 Years and older (Adult, Older Adult) |
NCT03578354 |
Pending |
|
January 2019 |
January 2023 |
January 2024 |
July 6, 2018 |
July 6, 2018 |
|
- Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
|
|
| 77 |
NCT03022838 |
Recruiting |
The Effects of Caffeine Withdrawal on Migraine |
- Migraine
- Caffeine Withdrawal
|
|
Interventional
|
Phase 2
Phase 3 |
- Nordlandssykehuset HF
- King's College London
- University Hospital of North Norway
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine days
- Withdrawal symptoms and/or syndrome (according to criteria)
- Migraine attacks
- (and 2 more...)
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03022838 |
2015/1729REK |
|
February 28, 2017 |
February 28, 2019 |
November 2019 |
January 18, 2017 |
December 29, 2017 |
|
- Nordland Hospital
Bodø, Norway - Departement of Neurology, NLSH HF
Bodø, Norway - Departement of Neurology
Tromsø, Norway
|
|
| 78 |
NCT03036761 |
Recruiting |
Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines |
|
- Procedure: Auriculotherapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of days with migraine and non-migraine headache post inclusion.
- Number of days with migraine post inclusion.
- Number of days with non migraine headache post inclusion.
- (and 4 more...)
|
90 |
Female |
18 Months to 80 Years (Child, Adult, Older Adult) |
NCT03036761 |
2016/58
2016-A01534-47 |
Migauric |
January 18, 2017 |
January 18, 2019 |
April 18, 2019 |
January 30, 2017 |
November 1, 2018 |
|
- Cabinet Médical
Maisons-Alfort, France - GHP Saint Joseph
Paris, France - Hopital Foch
Suresnes, France
|
|
| 79 |
NCT03337620 |
Recruiting |
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine |
|
|
Interventional
|
Phase 3 |
- Tian Medical Inc.
- TAMM Net, Inc.
- Clinvest Research, LLC
- New England Institute for Clinical Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Migraine Headaches During Treatment Phase
- Change in Number of Migraine Headache Days Post-Treatment
- Safety/Tolerability of TX360 Device Based on Adverse Effects
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03337620 |
16-001TI |
|
September 20, 2017 |
January 1, 2019 |
June 1, 2019 |
November 9, 2017 |
March 5, 2018 |
|
- Hartford Headache Center
East Hartford, Connecticut, United States - Waterbury Neurology
Middlebury, Connecticut, United States - Yale University
New Haven, Connecticut, United States - (and 5 more...)
|
|
| 80 |
NCT03055767 |
Recruiting |
Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population |
- Migraine Disorders
- Headache, Migraine
- Pediatrics
|
- Drug: OnabotulinumtoxinA
- Other: Placebo (Saline)
|
Interventional
|
Phase 2 |
- University of California, Irvine
- American Society of Regional Anesthesia
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain scores (Intensity)
- Change in duration of migraine episode
- Frequency of Migraine
- (and 8 more...)
|
26 |
All |
8 Years to 17 Years (Child) |
NCT03055767 |
UCIANES09 |
|
March 1, 2017 |
December 2019 |
March 2020 |
February 16, 2017 |
May 7, 2018 |
|
- Gottschalk Medical Plaza
Irvine, California, United States - UC Irvine Medical Center
Orange, California, United States
|
|
| 81 |
NCT03465826 |
Not yet recruiting |
Developing a Mobile Health Pain-Coping Skills Training Program for the Treatment of Chronic Migraine: AIM 4 |
- Chronic Migraine, Headache
|
- Behavioral: PainCOACH Pain Coping Skills Training
- Behavioral: Treatment as Usual
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
- Duke University
- Hackensack Meridian Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Feasibility and Engagement
- Change in Migraine Disability
- Change in HIT-6
- (and 4 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT03465826 |
18-01218 |
|
May 1, 2021 |
February 28, 2023 |
November 30, 2023 |
March 14, 2018 |
March 14, 2018 |
|
|
|
| 82 |
NCT03471039 |
Recruiting |
PACAP27 Headache Properties in Migraine Without Aura Patients |
|
- Drug: PACAP27
- Drug: Saline
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Health Services Research
|
- Headache Scores
- Facial blood flow (flushing)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT03471039 |
H-17016232 |
|
August 30, 2017 |
December 30, 2018 |
December 30, 2018 |
March 20, 2018 |
March 20, 2018 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 83 |
NCT01942486 |
Recruiting |
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine |
- Migraine Disorders
- Photophobia
|
- Device: Investigational Coating
|
Interventional
|
Not Applicable |
- University of Utah
- Primary Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIT-6 Score
- Headache Frequency as Measured Using a Self-Reporting Daily Diary
|
50 |
All |
7 Years to 18 Years (Child, Adult) |
NCT01942486 |
IRB_00065178 |
|
January 2014 |
October 2017 |
October 2017 |
September 16, 2013 |
May 3, 2017 |
|
- Moran Eye Center
Salt Lake City, Utah, United States
|
|
| 84 |
NCT03418766 |
Not yet recruiting |
The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Patients With Migraine |
- White Matter Disease
- Right-to-left Shunt
- Migraine Disorders
|
|
Observational
|
|
- First Hospital of Jilin University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- contrast-enhanced transcranial Doppler (c-TCD)
|
1500 |
All |
18 Years to 50 Years (Adult) |
NCT03418766 |
CAMBRAIN |
CAMBRAIN |
July 2018 |
July 2019 |
December 2020 |
February 1, 2018 |
July 13, 2018 |
|
|
|
| 85 |
NCT01470352 |
Recruiting |
Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention |
|
- Drug: Doluxetine
- Drug: Placebo
|
Interventional
|
Not Applicable |
- d_yarnitsky
- Rambam Health Care Campus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Therapeutic response to the analgesic drugs
|
100 |
Female |
18 Years to 50 Years (Adult) |
NCT01470352 |
Migrain-0265-11CTIL |
|
December 2011 |
September 2017 |
September 2018 |
November 11, 2011 |
September 27, 2017 |
|
- Rambam health care campus
Haifa, Israel
|
|
| 86 |
NCT03568617 |
Not yet recruiting |
rTMS for the Prevention Treatment of CM: a Single Arm Study |
|
|
Interventional
|
Not Applicable |
- Peking Union Medical College Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 50% reduction in the Number of Days with Headache
- 50% reduction in the Number of Migraine Days
- 50% reduction in the Number of Moderate/Severe Headache Days
- (and 6 more...)
|
15 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03568617 |
rTMSCM-PUMCH |
|
June 30, 2018 |
December 31, 2021 |
June 30, 2022 |
June 25, 2018 |
June 25, 2018 |
|
|
|
| 87 |
NCT02549898 |
Recruiting |
Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI |
- Migraine Headache
- Migraine Without Aura
|
- Drug: Feraheme
- Drug: Cilostazol
- Other: USPIO-MRI
- Other: BBI-MRI
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in USPIO uptake during attacks of unilateral migraine without aura compared to baseline
- Change in arterial wall thickness during attacks of unilateral migraine without aura compared to baseline
- Change in arterial circumference as a proxy measure for vascular inflammation during attacks of unilateral migraine without aura compared to baseline
- (and 3 more...)
|
42 |
Female |
18 Years to 50 Years (Adult) |
NCT02549898 |
H-15005669 |
|
August 2015 |
June 2018 |
June 2018 |
September 15, 2015 |
January 5, 2018 |
|
- Rigshospitalet Glostrup
Glostrup, Denmark
|
|
| 88 |
NCT03132233 |
Recruiting |
Energy for the Brain |
- Migraine
- Episodic Migraine
|
- Dietary Supplement: Beta-hydroxybutyrate calcium and magnesium salt
- Other: placebo powder
|
Interventional
|
Not Applicable |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of migraine days
- Number of headache days
- Acute migraine medication
- (and 3 more...)
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03132233 |
MigraKet |
MigraKet |
May 8, 2017 |
July 31, 2019 |
July 31, 2019 |
April 27, 2017 |
October 2, 2018 |
|
- University Children's Hospital (UKBB)
Basel, Basel-Stadt, Switzerland
|
|
| 89 |
NCT03472092 |
Recruiting |
Distinct Mechanisms of Cognitive Behavioral Therapy Effects in Youth With Migraine |
- Headache, Migraine
- Migraine
- Migraine Disorders
- Headache
|
- Behavioral: Cognitive Behavioral Therapy (CBT)
- Drug: Placebo
- Drug: Amitriptyline
|
Interventional
|
Phase 2 |
- Children's Hospital Medical Center, Cincinnati
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in functional resonance imaging (fMRI)
- Change in pain modulation
|
240 |
All |
10 Years to 17 Years (Child) |
NCT03472092 |
CIN0101-CAP Imaging Study |
|
October 2, 2018 |
December 2022 |
March 2023 |
March 21, 2018 |
October 2, 2018 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
|
| 90 |
NCT02447991 |
Recruiting |
Rizatriptan for Episodic Dizziness in Vestibular Migraine |
- Vestibular Migraine
- Migrainous Vertigo
|
- Drug: Rizatriptan
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Robert W. Baloh
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of treated vestibular migraine (VM) attacks in which subjects experience a reduction in severity rating
- Treatment Satisfaction at 48 hours
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02447991 |
IRB12-001549 |
|
December 2014 |
June 2019 |
June 2019 |
May 19, 2015 |
October 11, 2018 |
|
- University of California, Los Angeles
Los Angeles, California, United States - Mayo Clinic
Rochester, Minnesota, United States - ICAHN School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 91 |
NCT03666663 |
Not yet recruiting |
Sphenopalatine Ganglion Blocks RCT |
|
- Drug: Lidocaine
- Drug: Bupivacaine
- Drug: Ropivacaine
- Drug: Placebo
|
Interventional
|
Phase 4 |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction in headache days
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03666663 |
18-25736_SPG_2018.09 |
SPGblock |
February 1, 2019 |
October 1, 2022 |
October 1, 2023 |
September 12, 2018 |
December 4, 2018 |
|
- UCSF Headache Center
San Francisco, California, United States
|
|
| 92 |
NCT03269435 |
Recruiting |
Greater Occipital Nerve Block Versus Metoclopramide |
|
- Procedure: Greater occipital nerve block with bupivacaine
- Drug: Metoclopramide
|
Interventional
|
Phase 4 |
- Montefiore Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained headache relief
- Sustained headache freedom
- ED dwell time
- Improvement in 0-10 pain score
|
170 |
All |
18 Years and older (Adult, Older Adult) |
NCT03269435 |
2017-8249 |
|
November 1, 2017 |
August 2020 |
October 2020 |
August 31, 2017 |
December 12, 2017 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 93 |
NCT00727974 |
Recruiting |
Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines |
|
|
Observational
|
|
- Medical College of Wisconsin
- Children's Hospital and Health System Foundation, Wisconsin
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Identify novel genes that contribute to the risk of CVS using genomewide association analysis approach.
- Perform genotype-phenotype correlations between genetic profiles and various phenotypes of CVS (e.g. menstrual, Sato, calendar-tied) and migraine headaches (e.g. with aura, without aura, hemiplegic migraine)
|
880 |
All |
up to 21 Years (Child, Adult) |
NCT00727974 |
08/24
GC 607 |
|
January 2008 |
December 2019 |
December 2019 |
August 5, 2008 |
March 23, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 94 |
NCT03671681 |
Not yet recruiting |
Mindfulness Therapy for Chronic Migraine |
- Chronic Migraine
- Medication Overuse Headache
|
- Behavioral: Mindfulness
- Drug: Prophylactic
|
Interventional
|
Not Applicable |
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Headache frequency reduction
- Neuroimaging pattern
- Cost-efficacy
- (and 8 more...)
|
170 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03671681 |
Mind-CM |
Mind-CM |
November 2018 |
May 2021 |
November 2021 |
September 14, 2018 |
September 26, 2018 |
|
- Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit
Milano, Italy
|
|
| 95 |
NCT03539393 |
Available |
Expanded Access Program for Patients With Migraine |
|
|
Expanded Access
|
|
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
|
|
|
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03539393 |
TV48125-CNS-80005 |
|
|
|
|
May 28, 2018 |
May 28, 2018 |
|
|
|
| 96 |
NCT03727672 |
Recruiting |
Salivary Inflammatory Markers in Tension Type Headache and Migraine |
- Migraine
- Tension-Type Headache
|
|
Observational
|
|
- National and Kapodistrian University of Athens
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- migraine/Tension type Headache and C reactive protein
- migraine/Tension type Headache and Interleukin -1β
- migraine/Tension type Headache and Interleukin-6 levels
- (and 5 more...)
|
90 |
All |
Child, Adult, Older Adult |
NCT03727672 |
638/5.11.2015 |
SalHead |
January 1, 2016 |
October 30, 2018 |
October 30, 2018 |
November 1, 2018 |
November 1, 2018 |
|
- Eginition Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Athens, Greece
|
|
| 97 |
NCT03702114 |
Not yet recruiting |
Detecting Auricular Points in MMG by a Novel APD ( APD-MMG ) |
|
- Device: auricular point detection
|
Observational
|
|
- The University of Hong Kong
- Queen Mary Hospital, Hong Kong
- City University of Hong Kong
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- cohen's kappa coefficient
- the Visual Analogue Scale (VAS)
- the Modified New England Center of Headache (NECH) headache calendar
- (and 3 more...)
|
24 |
Female |
18 Years to 40 Years (Adult) |
NCT03702114 |
SCM-ACU-03 |
|
October 15, 2018 |
January 31, 2019 |
March 31, 2019 |
October 10, 2018 |
October 10, 2018 |
|
- Queen Mary Hospital, HKU
Hong Kong, Intl, Hong Kong
|
|
| 98 |
NCT03177616 |
Recruiting |
Integrative Migraine Pain Alleviation Through Chiropractic Therapy |
- Migraine
- Migraine Disorders
- Migraine With Aura
- (and 2 more...)
|
- Other: Chiropractic Treatment
|
Interventional
|
Not Applicable |
- Harvard University Faculty of Medicine
- Brigham and Women's Hospital
- Palmer Center for Chiropractic Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to the last four weeks of the intervention period in the number of migraine days.
- Changes from baseline to the post-intervention period in the number of migraine days.
- Number of responders
- (and 10 more...)
|
60 |
Female |
20 Years to 55 Years (Adult) |
NCT03177616 |
2017P000087 |
IMPACT |
June 7, 2017 |
June 2019 |
June 2019 |
June 6, 2017 |
October 29, 2018 |
|
- The Osher Clinical Center for Integrative Medicine at Brigham and Women's Hospital
Boston, Massachusetts, United States
|
|
| 99 |
NCT03341689 |
Recruiting |
Psilocybin for the Treatment of Migraine Headache |
|
- Drug: High Dose Psilocybin
- Drug: Low Dose Psilocybin
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Acute change in pain intensity
- Acute change in nausea/vomiting
- Acute change in photophobia
- (and 18 more...)
|
24 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03341689 |
1607018057.A |
|
November 1, 2017 |
November 1, 2019 |
March 1, 2020 |
November 14, 2017 |
December 8, 2017 |
|
- VA Connecticut Healthcare System, West Haven Campus
West Haven, Connecticut, United States
|
|
| 100 |
NCT03472378 |
Recruiting |
Can DFN-15 Terminate Migraine With Allodynia? |
- Migraine With Aura
- Migraine Without Aura
- Allodynia
|
- Drug: DFN-15
- Other: Placebo
|
Interventional
|
Phase 2 |
- Hartford Hospital
- Rami Burstein, PhD, Beth Israel Deaconess Medical Center
- Dr. Reddy's Laboratories Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Headache Pain Intensity
- Allodynia
|
100 |
All |
18 Years to 64 Years (Adult) |
NCT03472378 |
HHC-2017-0224 |
|
April 1, 2018 |
August 1, 2018 |
September 1, 2018 |
March 21, 2018 |
March 23, 2018 |
|
- Hartford HealthCare Headache Center
West Hartford, Connecticut, United States
|
|
Create an RSS feed from your search for:
Download the search results for: